TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12563
Drug: Intravenous 10
Normalized name: fat emulsion, intravenous 10% intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 10 mg tolamolol
Study: 12563
Drug: Intravenous 5
Normalized name: immune globulin intravenous 5% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 5 mg bufuralol
Study: 16722155
Drug: Conservative medical
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative medical therapy (Group A)
Study: 9282303
Drug: Scopolamine butylbromide
Normalized name: Scopolamine butylbromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine butylbromide at a daily dose of 60 mg t.i.d. (Group B)
Study: 3028457
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg enalapril orally
Study: 29914530
Drug: Fibrinogen concentrate
Normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen concentrate (6 g)
Study: 12534645
Drug: Ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 200 mg twice daily for 7 days
Study: 27128837
Drug: GSK961081 800 µg
Normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GSK961081 800 µg and FP 500 µg concurrently via separate inhalers
Study: 27128837
Drug: FP 500 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP 500 µg alone
Study: 19198268
Drug: Ozonotherapy (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozonotherapy (intravenous infusion of ozonized physiological solution)
Study: 1894523
Drug: Lung hyperinflation
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung hyperinflation and suctioning (three lung hyperinflation breaths at volumes of 12 cc/kg, 14 cc/kg, 16 cc/kg, or 18 cc/kg of lean body weight, followed by 10 seconds of continuous suction)
Study: 6873137
Drug: Scopolamine hydrobromide
Normalized name: Scopolamine Hydrobromide
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Scopolamine hydrobromide 0.3 mg and 0.9 mg (oral)
Study: 6873137
Drug: Scopolamine 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine 0.9 mg b.d. for 3 days (oral)
Study: 6873137
Drug: Ephedrine (alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine (alone and in combination with scopolamine)
Study: 6873137
Drug: Scopolamine hydrobromide
Normalized name: Scopolamine Hydrobromide
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Scopolamine hydrobromide 0.9 mg (oral)
Study: 6621852
Drug: Scopolamine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (various doses)
Study: 25128002
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor muscle training plus solifenacin (5 mg once daily)
Study: 17210771
Drug: Posaconazole at
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole at 800 mg/day as an oral suspension in divided doses
Study: 10863225
Drug: Augmented betamethasone
Normalized name: Augmented betamethasone dipropionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented betamethasone dipropionate 0.05% cream once daily in the first and third weeks and calcipotriene 0.005% ointment twice daily in the second and fourth weeks
Study: 10863225
Drug: Daily augmented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily augmented betamethasone dipropionate 0.05% cream for 4 weeks
Study: 26993881
Drug: Diclofenac (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (75 mg/3 mL intramuscular)
Study: 26993881
Drug: Paracetamol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1 g/100 mL intravenous)
Study: 26993881
Drug: Morphine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.1 mg/kg intravenous)
Study: 22313885
Drug: Qingre Huayu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingre Huayu herbs plus classic Western medical treatment (treatment group)
Study: 22313885
Drug: Classic Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classic Western medical treatment (control group)
Study: 10488294
Drug: Flumazenil administered
Normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flumazenil administered at the conclusion of the surgical procedure
Study: 10488294
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered at the conclusion of the surgical procedure
Study: 21564406
Drug: 17α-hydroxyprogesterone caproate
Normalized name: Hydroxyprogesterone Caproate
DrugBank: Hydroxyprogesterone caproate (DB06789)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17α-hydroxyprogesterone caproate 250 mg intramuscularly weekly from 16 weeks' gestation to 37 weeks' gestation
Study: 2308758
Drug: Self-administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration of morphine (PCA)
Study: 3919746
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of morphine
Study: 26585409
Drug: Antipsychotic review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic review
Study: 27640872
Drug: Antipsychotic review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic review and social interaction
Study: 25520427
Drug: Antimalarial chemoprevention
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antimalarial chemoprevention
Study: 19168412
Drug: Test ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Test ciprofloxacin (500 mg)
Study: 8431747
Drug: Anaesthetic solution
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaesthetic solution at 18 degrees C
Study: 8431747
Drug: Anaesthetic solution
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaesthetic solution at 37 degrees C
Study: 3038415
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg once-a-day
Study: 22541755
Drug: Moprid® (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moprid® (5 mg mosapride citrate tablets)
Study: 22541755
Drug: Gasmotin® (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gasmotin® (5 mg mosapride citrate tablets)
Study: 17589809
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone acetonide (IVT) 4 mg
Study: 2177158
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg ACTH 4-10
Study: 21990397
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + bevacizumab
Study: 20516273
Drug: Meal E
Normalized name: Oat meal extract
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meal E (200 ml of water)
Study: 18822919
Drug: Retention enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retention enema with compound glutamine entero‐soluble Capsule (CGC) and oral CGC (0.8 g, thrice a day)
Study: 15907596
Drug: FURP-lamivudine (test
Approvals — FDA: no, EMA: no, PMDA: no
Description: FURP-lamivudine (test formulation)
Study: 15907596
Drug: Epivir (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epivir (reference formulation)
Study: 8867907
Drug: GHRH (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH (100 micrograms in 1 ml saline)
Study: 8867907
Drug: Galanin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galanin (10 micrograms/kg in 100 ml saline) infusion for 60 minutes
Study: 8867907
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of galanin (10 micrograms/kg in 100 ml saline) and GHRH (100 micrograms in 1 ml saline)
Study: 1611439
Drug: MF 701
Normalized name: 3-MF
DrugBank: 3-Methylfentanyl (DB01571)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF 701 (100 mg intramuscularly once a day)
Study: 1611439
Drug: UFH (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFH (5000 units subcutaneously three times daily)
Study: 6422900
Drug: 5-hydroxytryptophan (5-HTP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-hydroxytryptophan (5-HTP), 200 mg orally
Study: 31299912
Drug: Community-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based intervention including an oral 20-25 min presentation in the language of participants about cervical cancer and screening.
Study: 20572865
Drug: Buccal brackets
Normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal brackets
Study: 20359269
Drug: Evening Primrose
Normalized name: EVENING PRIMROSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening Primrose Oil (EPO) 3,000 mg per day
Study: 18786318
Drug: Heparin 2
Normalized name: heparin 2 units/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 2 mg.kg(‐1).d(‐1) administered continuously via intravenous pump
Study: 14703408
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy + radiotherapy (GTRT group, n = 20) - SBN‐1 solution 1 x 10(12) VP injected intratumorally once a week for 8 weeks, radiotherapy started on the 3rd day of gene therapy, 5 fractions a week with a fraction dosage of 2 Gy and total dosage of 70 Gy
Study: 27565435
Drug: IIV4 (quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIV4 (quadrivalent influenza vaccine)
Study: 11902593
Drug: Weekly plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly plasma exchange, oral cyclophosphamide, and prednisone
Study: 11902593
Drug: Sham plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham plasma exchange and placebo medications
Study: 9295106
Drug: ACTH 4-10
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH 4-10 (2 mg)
Study: 30247596
Drug: Recombinant adjuvanted
Normalized name: zoster vaccine, recombinant adjuvanted intramuscular powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant adjuvanted zoster vaccine (HZ/su), administered in 2 doses separated by 60 days
Study: 30247596
Drug: Recombinant adjuvanted
Normalized name: zoster vaccine, recombinant adjuvanted intramuscular powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant adjuvanted zoster vaccine (HZ/su)
Study: 29328644
Drug: Triple eradication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple eradication therapy with probiotics (Lactobacillus Rosell‐52, Lactobacillus Rosell‐11, Bifidobacterium Rosell‐1755, Saccharomyces boulardii)
Study: 29328644
Drug: Triple eradication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple eradication therapy without probiotics
Study: 29328644
Drug: Triple eradication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple eradication therapy with probiotics
Study: 24788114
Drug: Child Development
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child Development Accounts (CDAs) offered to treatment participants, based on the Oklahoma 529 College Savings Plan
Study: 23158465
Drug: Chiropractic manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic manual therapy (individualized treatment of the spine)
Study: 9747065
Drug: 30-mg transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-mg transdermal nicotine patch
Study: 23403597
Drug: Dance intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dance intervention (dance classes twice weekly for 8 months, 75 minutes each class)
Study: 12972528
Drug: Combined-modality treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined-modality treatment (CMT)
Study: 3455945
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene kit with conventional toothbrush and self-teaching manual
Study: 25478585
Drug: Intra-articular corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular corticosteroid injection
Study: 16140428
Drug: L-arginine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (10 g daily for 4 weeks)
Study: 11947910
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg once daily for 8 weeks
Study: 2138493
Drug: Tetracycline (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline (500 mg b.d.)
Study: 2138493
Drug: Minocycline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (50 mg b.d.)
Study: 27397
Drug: 0.1% dimetindene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% dimetindene maleate gel
Study: 27397
Drug: 1% d‐chlorpheniramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% d‐chlorpheniramine maleate cream
Study: 27718765
Drug: Vaginal ALA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal ALA 400 mg daily for 30 days
Study: 20833455
Drug: Integrated pharmacology
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated pharmacology and medicines management curriculum
Study: 16886113
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy (5‐fluorouracil, pirarubicin, mitomycin) for two courses
Study: 16886113
Drug: Arterial infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arterial infusion chemotherapy (5‐fluorouracil, pirarubicin, mitomycin) for four courses
Study: 15800329
Drug: Temozolomide (TMZ)
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide (TMZ) 75 mg/m²/d orally concomitantly with RT (60 Gy in 30 fractions) followed by six cycles of TMZ (150 mg/m² on days 1-5 and 15-19 every 28 days)
Study: 20084326
Drug: Oral nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nifedipine (20 mg)
Study: 3720176
Drug: Healthy control
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy control subjects (not specified dosage)
Study: 28631582
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (GTE) 500 mg/d for 8 weeks
Study: 24669014
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (TPF)
Study: 21740089
Drug: Infrared-LED (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infrared-LED (850 nm) plus treadmill training (45 minutes twice a week for 3 months at 85%-90% HR(max), 39 mW/cm(2), fluence of 106 J/cm(2))
Study: 19908337
Drug: Fructose-sorbitol (F-S)
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fructose-sorbitol (F-S) ingestion (25 g fructose/5 g sorbitol)
Study: 19908337
Drug: Glucose ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose ingestion (50 g glucose)
Study: 15160331
Drug: Standard-dose adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose adjuvant chemotherapy
Study: 10978398
Drug: Dialysis dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysis dose (Kt/V) in conventional group
Study: 10978398
Drug: Dialysis dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysis dose (Kt/V) in experimental group
Study: 10978398
Drug: Erythropoietin doses
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin doses in conventional group
Study: 9565733
Drug: Augmenting agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmenting agent with SSRI antidepressant
Study: 9565733
Drug: SSRI antidepressant
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRI antidepressant
Study: 31483910
Drug: Resveratrol treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol treatment (800 mg/d for 40 days)
Study: 26290682
Drug: Ezetimibe/Simvastatin 10/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/Simvastatin 10/20 mg
Study: 16967147
Drug: Acetyl-salicylic acid
Normalized name: acetyl salicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-salicylic acid (aspirin)
Study: 2075082
Drug: Cefuroxime 1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 1,500 mg plus metronidazole 500 mg (3 doses)
Study: 6163343
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of RIA and enzyme studies
Study: 29469046
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) with AMO therapy
Study: 25132283
Drug: Conventional restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional restorative treatment with amalgam (CRT)
Study: 22642688
Drug: Human-voiced agent
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human-voiced agent with human-like gestures, facial expression, eye gaze, and body movement
Study: 20124127
Drug: Intracoronary eptifibatide
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary eptifibatide administration
Study: 16343039
Drug: Fenofibrate monotherapy
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate monotherapy
Study: 11998963
Drug: Transdermal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal therapy (17beta‐estradiol 0.05 mg/d + norethisterone acetate 0.25 mg/d)
Study: 9637637
Drug: Fentanyl-controlled ventilation
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl-controlled ventilation group (200 microg fentanyl: two doses of 50 microg and one dose of 100 microg, spaced 6 min)
Study: 2678520
Drug: Triampur (TP)
Normalized name: OTX-TP
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Triampur (TP) - doubled doses
Study: 811075
Drug: Carbamazepine in
Normalized name: carbamazepine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine in combination with phenobarbital and diphenylhydantoin
Study: 31160244
Drug: Internet-delivered Cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered Cognitive Behaviour Therapy (iCBT) for Fear of Birth
Study: 25919978
Drug: Pain interference
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain interference during treatment in COMBINE
Study: 25919978
Drug: Pain interference
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain interference following treatment in COMBINE
Study: 25919978
Drug: Pain interference
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain interference following treatment in COMBINE (after controlling for other factors)
Study: 3544622
Drug: Metoprolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (200 mg/day)
Study: 10825304
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no beta-blockers)
Study: 16424650
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ferrous iron supplement (as fumarate)
Study: 16424650
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg ferrous iron supplement (as fumarate)
Study: 7664435
Drug: d-sotalol 200
Normalized name: sotalol hydrochloride 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-sotalol 200 mg BID
Study: 7664435
Drug: d-sotalol 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-sotalol 50 mg BID
Study: 7664435
Drug: d-sotalol 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-sotalol 100 mg BID
Study: 31142156
Drug: Acupuncture (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (weekly for 3 months)
Study: 31142156
Drug: Phytoestrogens (soy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytoestrogens (soy isoflavones 75 mg/2/d for 3 months)
Study: 29390421
Drug: Celecoxib-based chemotherapy
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib-based chemotherapy
Study: 24911964
Drug: 7 mg
Normalized name: pectin 7 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 mg lycopene daily for 2 months
Study: 20347837
Drug: 12 weekly
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weekly classes of yoga
Study: 16477954
Drug: Morphine (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (intravenous injections of 0.1 mg/kg)
Study: 16477954
Drug: Placebo (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenous injections of 0.9% NaCl)
Study: 10500826
Drug: High anthracycline
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High anthracycline dose intensity (H/A)
Study: 10500826
Drug: Low anthracycline
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low anthracycline dose intensity (L/A)
Study: 2403448
Drug: Tamoxifen 40
Normalized name: tamoxifen 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 40 mg by mouth four times a day
Study: 23570538
Drug: Inpatient hybrid
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient hybrid closed-loop therapy (HCLC)
Study: 23570538
Drug: Outpatient sensor‐augmented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient sensor‐augmented pump (SAP) therapy
Study: 9232210
Drug: AMPT (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMPT (1 g p.o. T.I.D.)
Study: 29468069
Drug: Broad-spectrum antibiotics
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-spectrum antibiotics
Study: 30621711
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline treatment in blank and model groups
Study: 27193737
Drug: Supportive expressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive expressive group therapy (SET)
Study: 22682024
Drug: Interceptor long-lasting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interceptor long-lasting insecticidal nets (200 mg/m² alpha-cypermethrin)